Lexicon Pharma (LXRX) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.01 -1.47%
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: -600.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.16), in-line with the analyst estimate of ($0.16). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $50 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
